Clinical and Translational Radiation Oncology (Nov 2021)

Analysis of data to Advance Personalised Therapy with MR-Linac (ADAPT-MRL)

  • Jeremiah de Leon,
  • Amanda Woods,
  • Tania Twentyman,
  • Michael Meade,
  • Vicki Sproule,
  • Smitha Chandran,
  • Joseph Christiansen,
  • Neil Kennedy,
  • Maria Marney,
  • Kris Barooshian,
  • Michael Plit,
  • Jayd Lynch,
  • Raj Jagavkar,
  • Helen Ormandy,
  • John Christodouleas,
  • Florian Pietzsch,
  • Michael Chan,
  • Michael G Jameson

Journal volume & issue
Vol. 31
pp. 64 – 70

Abstract

Read online

Background: Analysis of Data to Advance Personalised Therapy with MR-Linac (ADAPT-MRL) is a multi-site, multinational, observational cohort registry designed to collect data on the use of the magnetic resonance linear accelerator (MR-Linac) for radiation therapy and patient outcomes. The registry will provide a linked repository of technical and clinical data that will form a platform for prospective studies and technology assessment. Methods: Design: This registry aims to include an estimated 10,000 eligible participants across Australia and other countries over a 7- to 10-year period. Participants will undergo treatment and assessments in accordance with standard practice. Toxicity and survival outcomes will be assessed at baseline, during treatment, and with 3 monthly follow-up until 24 months, patient reported outcome measures will also be collected. Participants with a variety of cancers will be included. Discussion: Data obtained from the ADAPT-MRL registry is expected to provide evidence on the safety and efficacy of the MR-Linac, a new technical innovation in radiation oncology. We expect this registry will generate data that will be used to optimise treatment techniques, MR-Linac software algorithms, evaluate participants’ outcomes and toxicities and to create a repository of adapted plans, anatomical and functional MR sequences linked to participants’ outcomes.

Keywords